Eriodictyol-7-O-glucoside
Based on 1 Customer Validation
Eriodictyol-7-O-glucoside (Eriodictyol 7-O-β-D-glucoside), a flavonoid, is an Nrf2 activator. Eriodictyol-7-O-glucoside exhibits significant scavenging effects on both hydroxyl radicals and superoxide anions, with IC50 values of 0.28 mM and 0.30 mM, respectively. Eriodictyol-7-O-glucoside increases the nuclear localization of Nrf2 and induces the expression of the Nrf2/ARE-dependent genes. Eriodictyol-7-O-glucoside provides protection against oxygen and glucose deprivation (OGD)-induced oxidative insult. Eriodictyol-7-O-glucoside demonstrates neuroprotective efficacy in a rat model of focal cerebral ischemia (MCAO). Eriodictyol-7-O-glucoside can be used for the study of stroke.
For research use only. We do not sell to patients.
- Purity: 99.42%
- CAS No.: 38965-51-4
- Formula: C21H22O11
- Molecular Weight:450.39
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
Natural Product Library
HY-L021
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Glycoside Compound Library
HY-L042
-
Lipid Compound Library
HY-L043
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Flavonoids Library
HY-L068
-
Neuroprotective Compound Library
HY-L070
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Food-Sourced Compound Library
HY-L094
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Heterocyclic Compound Library
HY-L138
-
Radioprotector Library
HY-L178
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
Tibetan Medicine Compound Library
HY-L191
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
Biological Activity
Nrf2[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| H9c2 | EC50 |
38.23 μM
Compound: 3
|
Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay
Cytoprotective activity against doxorubicin-induced cytotoxicity in rat H9c2 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 20932762] |
| HT-1080 | IC50 |
10 μM
Compound: Eriodictyol-7-O-glucoside
|
Anti-ferroptotic activity against Erastin-induced human HT-1080 cells assessed as inhibition of ferroptosis incubated for 72 hrs by CCK-8 assay
Anti-ferroptotic activity against Erastin-induced human HT-1080 cells assessed as inhibition of ferroptosis incubated for 72 hrs by CCK-8 assay
|
[PMID: 38996382] |
| RAW264.7 | IC50 |
41.2 μM
Compound: 10
|
Antiinflammatory activity against mouse RAW264.7 cells assessed as Inhibition of LPS-induced nitric oxide production after 24 hrs by ELISA
Antiinflammatory activity against mouse RAW264.7 cells assessed as Inhibition of LPS-induced nitric oxide production after 24 hrs by ELISA
|
[PMID: 20121165] |
Eriodictyol-7-O-glucoside (7.5-60 μM, 16 h) induces ARE-dependent luciferase activity in a dose-dependent manner in MDA-MB-231-ARE-Luc cells[1].
Eriodictyol-7-O-glucoside (0-80 μM, 0-24 h) increases Nrf2 protein level in a time-dependent and dose-dependent manner, while Keap1 level remains relatively unaffected in MDA-MB-231 cells and primary cultured astrocytes[1][[2].
Eriodictyol-7-O-glucoside (0-160 μM, 24 h) does not affect Nrf2 mRNA level but induces mRNA of HO-1, NQO1 and GCLC dose-dependently in MDA-MB-231 cells[1].
Eriodictyol-7-O-glucoside (0-80 μM, 24 h) increases Nrf2 protein level and the protein levels of HO-1, NQO1, and cGCS in a dose-dependent manner in HRMC cells[1].
Eriodictyol-7-O-glucoside (80 μM, 0-4 h) increases Nrf2 protein levels in nucleus with time and decreases Nrf2 levels in cytoplasm gradually in HRMC cells[1].
Eriodictyol-7-O-glucoside (0-80 μM, 24 h) shows a dose-dependent increase in intracellular glutathione levels in HRMC cells and primary cultured astrocytes[1][2].
Eriodictyol-7-O-glucoside (80 μM) cotreatment with Cisplatin (HY-17394) significantly improves cell survival in HRMC cells[1].
Eriodictyol-7-O-glucoside (20-80 μM, pretreatment for 2 h) reduces oxygen and glucose deprivation (OGD)-induced cell death, intracellular ROS levels, and cleaved caspase-3 expression in primary cultured astrocytes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 cells
-
Concentration:0, 20, 40, 80 μM
-
Incubation Time:0, 4, 6, 8, 24 h
-
Result:Increased Nrf2 protein level in a time-dependent and dose-dependent manner.
-
Cell Line:MDA-MB-231 cells
-
Concentration:0, 20, 40, 80 μM
-
Incubation Time:24 h
-
Result:Did not affect Nrf2 mRNA level.
Induced mRNA of HO-1, NQO1 and GCLC dose-dependently in MDA-MB-231 cells.
-
Cell Line:HRMC cells
-
Concentration:0, 20, 40, 80 μM
-
Incubation Time:0, 1, 2, 4, 24 h
-
Result:Increased Nrf2 protein level and the protein levels of HO-1, NQO1, and cGCS in a dose-dependent manner at 24 h.
Increased Nrf2 protein levels in nucleus with time and decreased Nrf2 levels in cytoplasm gradually.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Transient focal cerebral ischemia model in adult male SD rats was produced by intraluminal occlusion of the left middle cerebral artery (MCAO)[1]
-
Dosage:30 mg/kg
-
Administration:i.p. once daily for 5 days
-
Result:Upregulated the expression of Nrf2, HO-1, and γ-GCS in the cortex at 8 and 24 h after reperfusion.
Reduced infarct volume and improved neurological deficit scores at 24 h after reperfusion.
Decreased the number of TUNEL-positive cells in the ischemic cortex at 8 and 24 h after reperfusion.
Alleviated morphological damage of neurons in the cerebral cortex as shown by HE staining.
Chemical Information
-
CAS No. 38965-51-4
-
Appearance Solid
-
Molecular Weight 450.39
-
Formula C21H22O11
-
Color Off-white to light yellow
-
SMILES
O=C1C2=C(O)C=C(O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO)C=C2O[C@H](C4=CC(O)=C(C=C4)O)C1
-
Synonyms
Eriodictyol 7-O-β-D-glucoside
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 100 mg/mL (222.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Hu Q, et al. Eriodictyol-7-O-glucoside, a novel Nrf2 activator, confers protection against cisplatin-induced toxicity. Food Chem Toxicol. 2012 Jun;50(6):1927-32. [Content Brief]
[2]. Jing X, et al. Eriodictyol-7-O-glucoside activates Nrf2 and protects against cerebral ischemic injury. Toxicol Appl Pharmacol. 2013 Dec 15;273(3):672-9. [Content Brief]
[3]. Yao H, et al. Antioxidative flavanone glycosides from the branches and leaves of Viscum coloratum. Chem Pharm Bull (Tokyo). 2006 Jan;54(1):133-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2203 mL | 11.1015 mL | 22.2030 mL | 55.5074 mL |
| 5 mM | 0.4441 mL | 2.2203 mL | 4.4406 mL | 11.1015 mL | |
| 10 mM | 0.2220 mL | 1.1101 mL | 2.2203 mL | 5.5507 mL | |
| 15 mM | 0.1480 mL | 0.7401 mL | 1.4802 mL | 3.7005 mL | |
| 20 mM | 0.1110 mL | 0.5551 mL | 1.1101 mL | 2.7754 mL | |
| 25 mM | 0.0888 mL | 0.4441 mL | 0.8881 mL | 2.2203 mL | |
| 30 mM | 0.0740 mL | 0.3700 mL | 0.7401 mL | 1.8502 mL | |
| 40 mM | 0.0555 mL | 0.2775 mL | 0.5551 mL | 1.3877 mL | |
| 50 mM | 0.0444 mL | 0.2220 mL | 0.4441 mL | 1.1101 mL | |
| 60 mM | 0.0370 mL | 0.1850 mL | 0.3700 mL | 0.9251 mL | |
| 80 mM | 0.0278 mL | 0.1388 mL | 0.2775 mL | 0.6938 mL | |
| 100 mM | 0.0222 mL | 0.1110 mL | 0.2220 mL | 0.5551 mL |
Eriodictyol-7-O-glucoside Related Classifications
HY-N3847 Related Classifications
Powered by Bioz